165 related articles for article (PubMed ID: 35242698)
21. Enhancement of antitumor activity by using 5-ALA-mediated sonodynamic therapy to induce apoptosis in malignant gliomas: significance of high-intensity focused ultrasound on 5-ALA-SDT in a mouse glioma model.
Suehiro S; Ohnishi T; Yamashita D; Kohno S; Inoue A; Nishikawa M; Ohue S; Tanaka J; Kunieda T
J Neurosurg; 2018 Dec; 129(6):1416-1428. PubMed ID: 29350596
[TBL] [Abstract][Full Text] [Related]
22. Erythrocyte Membrane-Camouflaged IR780 and DTX Coloading Polymeric Nanoparticles for Imaging-Guided Cancer Photo-Chemo Combination Therapy.
Yang Q; Xiao Y; Yin Y; Li G; Peng J
Mol Pharm; 2019 Jul; 16(7):3208-3220. PubMed ID: 31145853
[TBL] [Abstract][Full Text] [Related]
23. Sinoporphyrin Sodium-Mediated Sonodynamic Therapy Inhibits RIP3 Expression and Induces Apoptosis in the H446 Small Cell Lung Cancer Cell Line.
Shen J; Cao S; Sun X; Pan B; Cao J; Che D; Jin S; Cao Y; Tian Y; Yu Y
Cell Physiol Biochem; 2018; 51(6):2938-2954. PubMed ID: 30562734
[TBL] [Abstract][Full Text] [Related]
24. Near-infrared/pH dual-responsive nanocomplexes for targeted imaging and chemo/gene/photothermal tri-therapies of non-small cell lung cancer.
Li Z; Zhu L; Liu W; Zheng Y; Li X; Ye J; Li B; Chen H; Gao Y
Acta Biomater; 2020 Apr; 107():242-259. PubMed ID: 32151700
[TBL] [Abstract][Full Text] [Related]
25. Gene augmented nuclear-targeting sonodynamic therapy via Nrf2 pathway-based redox balance adjustment boosts peptide-based anti-PD-L1 therapy on colorectal cancer.
Wan G; Chen X; Wang H; Hou S; Wang Q; Cheng Y; Chen Q; Lv Y; Chen H; Zhang Q
J Nanobiotechnology; 2021 Oct; 19(1):347. PubMed ID: 34715867
[TBL] [Abstract][Full Text] [Related]
26. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
27. Afatinib-loaded immunoliposomes functionalized with cetuximab: A novel strategy targeting the epidermal growth factor receptor for treatment of non-small-cell lung cancer.
Lu X; Liu S; Han M; Yang X; Sun K; Wang H; Mu H; Du Y; Wang A; Ni L; Zhang C
Int J Pharm; 2019 Apr; 560():126-135. PubMed ID: 30742982
[TBL] [Abstract][Full Text] [Related]
28. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
29. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Mukohara T; Engelman JA; Hanna NH; Yeap BY; Kobayashi S; Lindeman N; Halmos B; Pearlberg J; Tsuchihashi Z; Cantley LC; Tenen DG; Johnson BE; Jänne PA
J Natl Cancer Inst; 2005 Aug; 97(16):1185-94. PubMed ID: 16106023
[TBL] [Abstract][Full Text] [Related]
30. Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines.
Cavazzoni A; Alfieri RR; Cretella D; Saccani F; Ampollini L; Galetti M; Quaini F; Graiani G; Madeddu D; Mozzoni P; Galvani E; La Monica S; Bonelli M; Fumarola C; Mutti A; Carbognani P; Tiseo M; Barocelli E; Petronini PG; Ardizzoni A
Mol Cancer; 2012 Dec; 11():91. PubMed ID: 23234355
[TBL] [Abstract][Full Text] [Related]
31. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
32. Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin β1-driven Src-Akt bypass signaling.
Kim YJ; Jung K; Baek DS; Hong SS; Kim YS
Oncogene; 2017 May; 36(18):2543-2552. PubMed ID: 27797376
[TBL] [Abstract][Full Text] [Related]
33. Dual-function nanostructured lipid carriers to deliver IR780 for breast cancer treatment: Anti-metastatic and photothermal anti-tumor therapy.
Li H; Wang K; Yang X; Zhou Y; Ping Q; Oupicky D; Sun M
Acta Biomater; 2017 Apr; 53():399-413. PubMed ID: 28159715
[TBL] [Abstract][Full Text] [Related]
34. IR780 Based Sonotherapeutic Nanoparticles to Combat Multidrug-Resistant Bacterial Infections.
Huang B; Wang L; Tang K; Chen S; Xu Y; Liao H; Niu C
Front Chem; 2022; 10():840598. PubMed ID: 35141201
[TBL] [Abstract][Full Text] [Related]
35. Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC.
Zhang Y; Yang J; Ding M; Li L; Lu Z; Zhang Q; Zheng J
Oncol Lett; 2016 Nov; 12(5):3241-3249. PubMed ID: 27899989
[TBL] [Abstract][Full Text] [Related]
36. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
[TBL] [Abstract][Full Text] [Related]
38. Oxygen-sufficient lipid nanobubbles combined with UTMD for enhanced sonodynamic therapy of Hep-G2 cells.
Tan H; Tian Y; Yang H; Liu Z; Liang X; Li B; Cheng W
J Biomed Mater Res B Appl Biomater; 2021 Nov; 109(11):1796-1806. PubMed ID: 33838006
[TBL] [Abstract][Full Text] [Related]
39. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
[TBL] [Abstract][Full Text] [Related]
40. CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo.
Zhang K; Wang L; Wei A; Jia X; Liu X
Thorac Cancer; 2020 Jun; 11(6):1566-1577. PubMed ID: 32368855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
